Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom’s fair value price target has been tweaked from ...

If you are wondering whether DexCom's current share price lines up with its underlying worth, or if the market is mispricing the stock, this article walks through that question step by step. DexCom ...

DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...

DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...

DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years ...

DexCom (NASDAQ:DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, ...

Shares of DexCom (NASDAQ: DXCM), a medical device specialist, have lagged the market this year. However, the true test of a company isn't how it performs over a relatively short period, such as eight ...